Welcome to our dedicated page for QIA news (Ticker: QIA), a resource for investors and traders seeking the latest updates and insights on QIA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect QIA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of QIA's position in the market.
QIAGEN has launched the QIAsphere cloud-based platform, enabling labs and QIAstat-Dx users to monitor testing and instrument status continuously. This platform enhances syndromic testing by providing real-time visibility across multiple instruments, thereby reducing downtime and improving efficiency. QIAsphere will also allow technical service teams to offer rapid support. Initially marketed for the QIAcube Connect platform, it will soon extend to other molecular diagnostics solutions. This innovation is expected to bring molecular testing closer to patients.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has launched the QIAcube Connect MDx, an automated sample processing platform for molecular diagnostic labs in the U.S., Canada, and the EU. This enhanced instrument supports in-vitro diagnostic applications and is compatible with over 80 QIAGEN kits. With over 9,800 QIAcube instruments deployed by end of 2020, this new version follows strict medical device standards, improving lab safety and workflow efficiency. It automates the processing of SARS-CoV-2 and other viral samples, standardizing multiple sample purification.
QIAGEN and INOVIO Pharmaceuticals have extended their partnership with a master collaboration agreement to develop liquid biopsy-based diagnostic products utilizing next-generation sequencing (NGS) technology. The initial project will focus on a diagnostic test for identifying women who may benefit from VGX-3100, INOVIO's immunotherapy for advanced cervical dysplasia linked to HPV. This test will leverage QIAGEN’s bioinformatics to enhance INOVIO’s biomarker signature and will be developed for the Illumina NextSeq 550Dx platform, following a partnership established in 2019.
QIAGEN has appointed Thomas Ebeling to its Supervisory Board, effective immediately. Ebeling, with a robust background in healthcare and management, previously served as CEO of ProSiebenSat.1 Media and held significant roles at Novartis. This addition expands the Board to eight members, enhancing its expertise in Life Sciences and diagnostics. Lawrence Rosen, Chairman of the Supervisory Board, emphasized the commitment to corporate governance and value creation for stakeholders.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) reported robust fourth-quarter and full-year 2020 results, surpassing net sales and adjusted earnings targets. Q4 net sales rose 38% to $571.2 million, exceeding the 32% CER growth outlook. Adjusted EPS for Q4 increased 42% to $0.68. Full-year net sales grew 23% to $1.87 billion, surpassing the 22% CER outlook, with adjusted EPS rising to $2.15. CEO Thierry Bernard highlighted strong COVID-19 testing demand alongside growth in non-COVID areas, ensuring confidence in 2021 performance amid ongoing strategic initiatives.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) plans to resubmit its QIAreach SARS-CoV-2 Antigen Test to the U.S. FDA for Emergency Use Authorization in Q1 2021 after withdrawing its initial submission in November 2020 due to a chemistry-related issue. The company believes the issue has been resolved and is currently collecting data for resubmission. QIAGEN's CEO, Thierry Bernard, emphasized their commitment to expediting the process to assist in COVID-19 testing. Despite this, the company does not expect any impact on its full-year 2021 sales or adjusted earnings.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) confirmed that its PCR tests for SARS-CoV-2 remain effective against known viral variants. Since May 2020, assessments of the tests against genetic mutations have shown no impact on sensitivity. The company will continue biweekly surveillance of genetic variations. Chief Medical Officer Davide Manissero emphasized the importance of genomic sequencing in monitoring the virus. The report highlights variants like VUI 202012/01, 501Y.V2, and B.1.1.28 P1, which pose increased transmissibility risks.
